<VariationArchive RecordType="classified" VariationID="417368" VariationName="NC_000023.10:g.(?_153287264)_(153363188_?)dup" VariationType="Duplication" Accession="VCV000417368" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-08-06" DateCreated="2017-04-17" MostRecentSubmission="2017-04-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="404014" VariationID="417368">
      <GeneList>
        <Gene Symbol="MECP2" FullName="methyl-CpG binding protein 2" GeneID="4204" HGNC_ID="HGNC:6990" Source="submitted" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>Xq28</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="154021573" stop="154097717" display_start="154021573" display_stop="154097717" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="153287263" stop="153363187" display_start="153287263" display_stop="153363187" Strand="-" />
          </Location>
          <OMIM>300005</OMIM>
          <Haploinsufficiency last_evaluated="2021-02-22" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=MECP2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-02-22" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=MECP2">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NC_000023.10:g.(?_153287264)_(153363188_?)dup</Name>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>Xq28</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" innerStart="153287264" innerStop="153363188" display_start="153287264" display_stop="153363188" variantLength="75925" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.(?_153287264)_(153363188_?)dup" Assembly="GRCh37">
            <Expression>NC_000023.10:g.(?_153287264)_(153363188_?)dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000023.10:g.(?_153287264)_(153363188_?)dup AND multiple conditions" Accession="RCV000467623" Version="1">
        <ClassifiedConditionList TraitSetID="31136">
          <ClassifiedCondition DB="MedGen" ID="C0162635">Angelman syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0035372">Rett syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0796222">X-linked intellectual disability-psychosis-macroorchidism syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2016-10-27" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2016-10-27" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2017-04-17" MostRecentSubmission="2017-04-17">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="31136" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2902" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">X-linked intellectual disability-psychosis-macroorchidism syndrome</ElementValue>
                <XRef ID="MONDO:0010235" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PPM-X syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">INTELLECTUAL DEVELOPMENTAL DISORDER, X-LINKED, SYNDROMIC 13</ElementValue>
                <XRef Type="MIM" ID="300055" DB="OMIM" />
                <XRef Type="Allelic variant" ID="300005.0009" DB="OMIM" />
                <XRef Type="Allelic variant" ID="300005.0017" DB="OMIM" />
                <XRef Type="Allelic variant" ID="300005.0022" DB="OMIM" />
                <XRef Type="Allelic variant" ID="300005.0033" DB="OMIM" />
                <XRef Type="Allelic variant" ID="300005.0015" DB="OMIM" />
                <XRef Type="Allelic variant" ID="300005.0035" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MRXS13</ElementValue>
                <XRef Type="MIM" ID="300055" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The spectrum of MECP2-related phenotypes in females ranges from classic Rett syndrome to variant Rett syndrome with a broader clinical phenotype (either milder or more severe than classic Rett syndrome) to mild learning disabilities; the spectrum in males ranges from severe neonatal encephalopathy to pyramidal signs, parkinsonism, and macroorchidism (PPM-X) syndrome to severe syndromic/nonsyndromic intellectual disability. Females: Classic Rett syndrome, a progressive neurodevelopmental disorder primarily affecting girls, is characterized by apparently normal psychomotor development during the first six to 18 months of life, followed by a short period of developmental stagnation, then rapid regression in language and motor skills, followed by long-term stability. During the phase of rapid regression, repetitive, stereotypic hand movements replace purposeful hand use. Additional findings include fits of screaming and inconsolable crying, autistic features, panic-like attacks, bruxism, episodic apnea and/or hyperpnea, gait ataxia and apraxia, tremors, seizures, and acquired microcephaly. Males: Severe neonatal-onset encephalopathy, the most common phenotype in affected males, is characterized by a relentless clinical course that follows a metabolic-degenerative type of pattern, abnormal tone, involuntary movements, severe seizures, and breathing abnormalities. Death often occurs before age two years.</Attribute>
                <XRef ID="NBK1497" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3506" />
                <XRef ID="3506" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301670</ID>
                <ID Source="BookShelf">NBK1497</ID>
              </Citation>
              <XRef ID="3077" DB="Orphanet" />
              <XRef ID="C0796222" DB="MedGen" />
              <XRef ID="MONDO:0010235" DB="MONDO" />
              <XRef Type="MIM" ID="300055" DB="OMIM" />
            </Trait>
            <Trait ID="404" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Angelman syndrome</ElementValue>
                <XRef ID="Angelman+Syndrome/452" DB="Genetic Alliance" />
                <XRef ID="MONDO:0007113" DB="MONDO" />
                <XRef ID="76880004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Happy puppet syndrome (formerly)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">HAPPY PUPPET SYNDROME</ElementValue>
                <XRef Type="MIM" ID="105830" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">AS</ElementValue>
                <XRef Type="MIM" ID="105830" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000260593" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508937" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509438" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522320" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000529013" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551668" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558906" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592359" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000331374" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507771" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508896" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000519272" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520979" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520995" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520998" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558805" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000226643" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000519582" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527540" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530118" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531722" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552341" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000556577" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558215" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000568029" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000503131" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520996" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521642" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000525860" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000525867" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530102" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552178" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552326" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000556612" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558216" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000568371" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="mode of inheritance">AS is caused by disruption of maternally imprinted UBE3A located within the 15q11.2-q13 Angelman syndrome/Prader-Willi syndrome (AS/PWS) region.</Attribute>
                <XRef ID="GTR000501320" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Angelman syndrome (AS) is characterized by severe developmental delay or intellectual disability, severe speech impairment, gait ataxia and/or tremulousness of the limbs, and unique behavior with an apparent happy demeanor that includes frequent laughing, smiling, and excitability. Microcephaly and seizures are also common. Developmental delays are first noted at around age six months; however, the unique clinical features of AS do not become manifest until after age one year.</Attribute>
                <XRef ID="NBK1144" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="mode of inheritance">imprinting disorder</Attribute>
                <XRef ID="GTR000260593" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5810" />
                <XRef ID="5810" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301323</ID>
                <ID Source="BookShelf">NBK1144</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2001">
                <ID Source="pmc">3111049</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="Eurogentest, 2008">
                <URL>http://www.eurogentest.org/web/files/public/unit3/ClinicalUtilityGeneCards/Indication%20criteria%20-%20AS.pdf</URL>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23519317</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESHG/ASHG, 2015">
                <ID Source="PubMed">25782669</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27467454</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2020">
                <ID Source="PubMed">32296163</ID>
              </Citation>
              <XRef ID="72" DB="Orphanet" />
              <XRef ID="C0162635" DB="MedGen" />
              <XRef ID="MONDO:0007113" DB="MONDO" />
              <XRef Type="MIM" ID="105830" DB="OMIM" />
            </Trait>
            <Trait ID="3622" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Rett's disorder</ElementValue>
                <XRef ID="Rett+syndrome/6294" DB="Genetic Alliance" />
                <XRef ID="68618008" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Autism, dementia, ataxia, and loss of purposeful hand use</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Rett syndrome</ElementValue>
                <XRef ID="MONDO:0010726" DB="MONDO" />
                <XRef ID="778" DB="Orphanet" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">RTT</ElementValue>
                <XRef Type="MIM" ID="312750" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">RTS</ElementValue>
                <XRef Type="MIM" ID="312750" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5696" />
                <XRef ID="5696" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">The spectrum of MECP2-related phenotypes in females ranges from classic Rett syndrome to variant Rett syndrome with a broader clinical phenotype (either milder or more severe than classic Rett syndrome) to mild learning disabilities; the spectrum in males ranges from severe neonatal encephalopathy to pyramidal signs, parkinsonism, and macroorchidism (PPM-X) syndrome to severe syndromic/nonsyndromic intellectual disability. Females: Classic Rett syndrome, a progressive neurodevelopmental disorder primarily affecting girls, is characterized by apparently normal psychomotor development during the first six to 18 months of life, followed by a short period of developmental stagnation, then rapid regression in language and motor skills, followed by long-term stability. During the phase of rapid regression, repetitive, stereotypic hand movements replace purposeful hand use. Additional findings include fits of screaming and inconsolable crying, autistic features, panic-like attacks, bruxism, episodic apnea and/or hyperpnea, gait ataxia and apraxia, tremors, seizures, and acquired microcephaly. Males: Severe neonatal-onset encephalopathy, the most common phenotype in affected males, is characterized by a relentless clinical course that follows a metabolic-degenerative type of pattern, abnormal tone, involuntary movements, severe seizures, and breathing abnormalities. Death often occurs before age two years.</Attribute>
                <XRef ID="NBK1497" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">MECP2-Related Disorders</Attribute>
                <XRef ID="NBK1497" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301670</ID>
                <ID Source="BookShelf">NBK1497</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2008">
                <ID Source="pmc">3111012</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23519317</ID>
              </Citation>
              <XRef ID="3095" DB="Orphanet" />
              <XRef ID="778" DB="Orphanet" />
              <XRef ID="C0035372" DB="MedGen" />
              <XRef ID="MONDO:0010726" DB="MONDO" />
              <XRef Type="MIM" ID="312750" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1076748" SubmissionDate="2017-03-14" DateLastUpdated="2017-04-17" DateCreated="2017-04-17">
        <ClinVarSubmissionID localKey="1098730|MedGen:C0035372;C0162635;C1968550" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000563831" DateUpdated="2017-04-17" DateCreated="2017-04-17" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-10-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment Type="public">A gross duplication of the genomic region encompassing the full coding sequence of the MECP2 gene has been identified. The boundaries of this event are unknown as the duplication extends beyond the assayed region for this gene and therefore may encompass additional genes. As the precise location of this duplication is unknown, it may be in tandem or it may be located elsewhere in the genome. Gross duplications of the genomic region encompassing MECP2 have been reported in individuals with developmental delay, intellectual disability, autism, hypotonia, macrocephaly, and/or seizures. These duplications and are known to cause MECP2 duplication syndrome (PMID: 18985075, 16080119, 17172942, 18385275, 20177701). Experimental studies have shown that overexpression of MECP2 in a mouse model recapitulates all the symptoms associated with MECP2 duplication syndrome in humans, including neuronal excitation, seizures, progressive neurological deficiencies and immunological abnormalities (PMID: 15351775, 23220634). Importantly, the expression level of MECP2 in mice correlates with neuronal excitation; knockout of MECP2 results in decreased long-term potentiation (LTP) in neurons while overexpression of MECP2 shows increased LTP (PMID: 17920015), consistent with dosage sensitivity of the MECP2 gene. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MECP2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000023.10:g.(?_153287264)_(153363188_?)dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0035372" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0162635" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1968550" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2017March_Invitae</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1076748" TraitType="Disease" MappingType="XRef" MappingValue="C1968550" MappingRef="MedGen">
        <MedGen CUI="C0796222" Name="X-linked intellectual disability-psychosis-macroorchidism syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1076748" TraitType="Disease" MappingType="XRef" MappingValue="C0162635" MappingRef="MedGen">
        <MedGen CUI="C0162635" Name="Angelman syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1076748" TraitType="Disease" MappingType="XRef" MappingValue="C0035372" MappingRef="MedGen">
        <MedGen CUI="C0035372" Name="Rett syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

